.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Accenture
Chubb
Boehringer Ingelheim
US Department of Justice
Citi
Mallinckrodt
McKesson
Healthtrust
Deloitte

Generated: September 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020859

« Back to Dashboard
NDA 020859 describes SONATA, which is a drug marketed by Pfizer and is included in one NDA. It is available from six suppliers. Additional details are available on the SONATA profile page.

The generic ingredient in SONATA is zaleplon. There are twelve drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the zaleplon profile page.

Summary for NDA: 020859

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Sedatives/Hypnotics
Formulation / Manufacturing:see details

Pharmacology for NDA: 020859

Suppliers and Packaging for NDA: 020859

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SONATA
zaleplon
CAPSULE;ORAL 020859 NDA Rebel Distributors Corp. 21695-105 21695-105-14 14 CAPSULE in 1 BOTTLE, PLASTIC (21695-105-14)
SONATA
zaleplon
CAPSULE;ORAL 020859 NDA Rebel Distributors Corp. 21695-105 21695-105-30 30 CAPSULE in 1 BOTTLE, PLASTIC (21695-105-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength5MG
Approval Date:Aug 13, 1999TE:ABRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength10MG
Approval Date:Aug 13, 1999TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 020859

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
SONATA
zaleplon
CAPSULE;ORAL020859-001Aug 13, 1999► Subscribe► Subscribe
Pfizer
SONATA
zaleplon
CAPSULE;ORAL020859-002Aug 13, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Mallinckrodt
Johnson and Johnson
Healthtrust
Citi
Argus Health
UBS
Medtronic
AstraZeneca
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot